Telix Pharmaceuticals (ASX:TLX) launches NOBLE Registry

Company News

by Adrian Tan

Telix Pharmaceuticals (ASX:TLX), a nuclear medicine company focusing on unmet needs for patients with cancer, has announced the launch of the "Nobody Left Behind" ("NOBLE") Registry.

The aim of the registry is to collect data on the clinical use of TLX599-CDx. TLX599-CDx is a prostate cancer imaging product being developed by Telix. It uses widely available SPECT technology (single-photo emission computer tomography).

Telix CEO Dr Christian Behrenbruch comments, “We are honoured to support the launch of the NOBLE Registry, which represents the very essence of our belief that every patient deserves access to the benefits of nuclear medicine."

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.